Asset Details
Do you wish to reserve the book?
Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study
Do you wish to request the book?
Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study
2015
Overview
Background
Healthcare systems spend considerable proportions of their budgets on pharmaceutical treatment of hypertension, hyperlipidemia, and diabetes mellitus. From data on almost all residents of Austria, a country with mandatory health insurance and universal health coverage, we estimated potential cost savings by substituting prescribed medicines with the cheapest medicines that were of the same chemical substance and strength, and available during the same time.
Methods
Data from 8.3 million persons (98.5 % of the total Austrian insured population) from 2009–2012 were analyzed. Real prescription costs for antihypertensive, lipid-lowering, and hypoglycemic medicines achievable by same-substance, same-strength drug substitution were computed for each active ingredient, and per gender and 1-year age category of patients.
Results
In 2012, health insurance providers spent €231.3 million, €77.8 million, and €91.9 million for antihypertensive, lipid-lowering, and diabetes medications, of which €52.2 million (22.6 %), €15.9 million (20.5 %), and €4.1 million (4.5 %), respectively, could have been saved by same-substance drug substitution. Highest potential savings were calculated for amlodipine (€8.0 million, 65.4 %), simvastatin (€12.2 million, 59.3 %), and metformin (€2.4 million, 54.6 %), respectively. Higher savings for men than for women resulted from differing prescribed cumulative dosages and proportions of patients with co-payment waiver. Potential cost savings in antihypertensive and lipid-lowering drugs increased from 2009–2012.
Conclusion
Our study highlights the cost-savings potential from arguably the most acceptable of interventions, simply switching to the cheapest available same-substance, same-strength product. In 2012, this strategy could have reduced costs for antihypertensive, lipid-lowering, and hypoglycemic treatment by up to 18.0 %.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
Antihypertensive Agents - economics
/ Austria
/ Budgets
/ Costs
/ Diabetes
/ Diabetes Mellitus - drug therapy
/ Drug Costs - statistics & numerical data
/ Drugs
/ Humans
/ Hyperlipidemias - drug therapy
/ Hypoglycemic Agents - economics
/ Hypolipidemic Agents - economics
/ Lipids
/ Medicine
/ Patients
/ Pharmacoeconomics and Health Outcomes
/ Pharmacy
/ Savings
/ Studies
